EEG biosignatures are sensitive and specific markers that distinctively characterize Parkinson's Disease, Lewy Body Dementia and Alzheimer's Disease

Background: Parkinson ’s Disease (PD) and Lewy Body Dementia (LBD) patients exhibit a range of motor, psychiatric, and cognitive symptoms associated with different stages of disease progression. There is a need for accurate, inexpensive biomarkers for early detection of the underlying pathology and to assess treatment efficacy. EEG biosignatures provide objective quantification of neurodegenerative disease and differentiate between PD, LBD and Alzheimer’s Dementia (AD) to map the trajectory of neurodegeneration and evaluate efficacy of novel disease-modifying treatments.

Source: Parkinsonism and Related Disorders - May 1, 2024 Category: Neurology Authors: C. Berka, A. Meghdadi, A. Verma, E. St. Louis, B. Boeve, C. Henchcliffe, D. Mozley Source Type: research